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Repeated noninvasive imaging of reporter gene expression is increasingly used for monitoring the expression and loca-
tion of genes and cells in experimental animals and humans. Development of transgenic animals that express reporter 
genes in specific tissues/organs or the whole body possess the potential for understanding the course of disease or serve 
as a syngenic cell/tissue/organ donor to study transplant survival in recipients. In this review, we discuss the major 
reporter genes used in gene therapy, cell therapy and transgenic animals, including exogenous reporters (herpes simplex 
virus type 1 thymidine kinase, fluorescent proteins and luciferase) and endogenous reporters (dopamine 2 receptor, 
transferrin receptor, sodium iodide symporter, β-glucuronidase, and antibody reporter). The clinical potential of these 
reporter genes is also discussed with regard to their imaging specificity and immunogenicity in humans.
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Applications of Reporter Gene Imaging
The availability of sensitive and specific reporter 
genes play a critical role in determining the mech-
anisms of gene expression in transgenic animals 
and in developing gene delivery systems for human 
gene therapy. Current reporter genes can be dis-
tinguished into several categories including: (1) 
transporter-based reporters that constitutively 
transport radioactive ions into transduced cells; 
(2) enzyme-based reporters that selectively interact 
with a radioactive or fluorescent substrate, result-
ing in trapping and accumulation of the substrate; 
(3) fluorescent proteins that emit natural fluoresces 
without additional substrates; and (4) membrane-
anchored receptors or antibodies that can specifically 
trap ligands, antigens or haptens labelled with radio-
active, magnetic or fluorescent probes (Figure 1).
Noninvasive imaging methods allow unambiguous 
identification of the location and extent of reporter 
genes. Typically, there are three major methods 
for noninvasive imaging of reporter genes based on 
optical imaging, magnetic resonance (MR) imaging, 
and nuclear medicine imaging. Most reporter genes 
are suitable for a specific imaging system. For ex-
ample, herpes simplex virus type 1 thymidine kinase 
(HSV1-tk) can phosphorylate radiolabeled acyclogua-
nosine and uracil nucleoside derivatives,1−7 allowing 
selective retention of these radiolabeled substrates 
inside cells, which can be detected by nuclear med-
icine imaging.1,8,9 However, each imaging modality 
has its strengths and weaknesses. For example, nu-
clear medicine imaging is highly sensitive but suffers 
from poor spatial resolution.10 MR imaging has spec-
tacular image resolution, but imaging sensitivity is 
inferior to nuclear techniques.11 Optical imaging is 
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a relatively inexpensive, robust way of measuring 
gene expression in the laboratory but may be limited 
by the shallow depth penetration of the signal.12 
No imaging system fulfills all purposes. Thus, the 
development of a versatile reporter that can be 
monitored by multiple imaging systems will allow 
researchers to choose appropriate imaging technol-
ogies to meet the demands of biomedical research. 
Moreover, the clinical application of imaging re-
porter gene technology is also facilitated by the 
use of multimodality reporter genes.
Exogenous Reporter Genes
HSV1-tk
HSV1-tk is the most commonly used reporter gene 
(known as the gold standard reporter gene) for cur-
rent molecular imaging studies using radiolabeled 
probes and nuclear medicine imaging, including 
single photon emission computed tomography8 and 
positron emission tomography (PET)1,9,13 (Figure 2). 
Similar to mammalian thymidine kinase type 1 
(TK1), HSV1-tk is an enzyme that converts thymidine 
to its phosphorylated form. However, HSV1-tk has 
less substrate specificity than mammalian TK1 and 
can phosphorylate a wide range of uracil nucleoside 
derivatives (e.g. 5-iodo-2-fluoro-2-deoxy-1-β-D-
arabino-furanosyl-uracil [FIAU]2 and 5-ethyl-2-
fluoro-2-deoxy-1-β-D-arabino-furanosyl-uracil 
[FEAU]1,3) and acycloguanosine derivatives (e.g. acy-
clovir,4 ganciclovir,5 and 9-(4-fluoro-3(hydoxymethyl)
butyl) guanine [FHBG]1,6,14), whereas mammalian 
TK1 has limited or no ability to phosphorylate these 
compounds.15 This difference between mammalian 
TK1 and HSV1-tk enables the development and 
usage of radiolabeled probes that are selectively 
phosphorylated by HSV1-tk for noninvasive imaging 
of genes and cells, as well as transgenic animals.16,17 
The second-generation HSV1-sr39tk,18 a mutant 
HSV1-tk with five amino acid substitutions, can re-
duce the detection limit of HSV1-tk. HSV1-sr39tk is 
effective for utilizing positron emitting acyclogua-
nosine substrates, most commonly FHBG.19 The 
combination of HSV1-sr39tk and FHBG is currently 
one of the most effective PET systems.20
HSV1-tk can be simultaneously used as a reporter 
gene and as a therapeutic gene in gene therapy 
protocols against viral infected diseases and tumors. 
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Figure 1 Different reporter gene systems. When the reporter gene is transduced into target cells by a delivery vec-
tor (viral or non-viral), the reporter gene may integrate into the host genome or remain in the cytosol. After the ini-
tiation of reporter gene transcription, the reporter gene product can be either a membrane antibody, a membrane 
receptor, a fluorescent protein, cytoplasmic or membrane enzyme, or a membrane transporter. A complementary 
imaging probe (e.g. a radioactive, magnetic, fluorescent or bioluminescent molecule) is administered and the probe 
concentrates at the site of reporter gene expression. The level of reporter probe concentration as well as the inten-
sity of the imaging signal is usually proportional to the level of reporter gene expression. mRNA: messenger RNA.
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The acycloguanosines, which are phosphorylated by 
HSV1-tk, can kill cells by either blocking DNA syn-
thesis or causing chain termination.4 Gan ciclovir is 
commonly used as prodrug in this suicide gene ther-
apy. However, this property of HSV1-tk may become 
a disadvantage in monitoring the delivery and sur-
vival of transplant cells, such as stem cells and beta 
cells.21 In addition, HSV1-tk and HSV1-sr39tk are 
viral products that provoke a remarkable immune 
response against cells or tissues transduced with 
these genes.22
To avoid immunogenicity of nonhuman reporter 
protein, human mitochondrial thymidine kinase 
type 2 (hTK2) was developed as a human reporter 
gene.23 It is minimally expressed in mitochondria 
of most human tissue and has a spectrum of sub-
strate specificity similar to that of HSV1-tk. The 
reporter gene hTK2 can efficiently phosphorylate 
FIAU and FEAU but is limited in phosphorylating 
FHBG.23 The reporter gene hTK2 may provide an 
alternative human thymidine kinase reporter sys-
tem for use in human subjects.
Fluorescent proteins
Fluorescent proteins, such as green fluorescent pro-
tein (GFP), yellow fluorescent protein and red flu-
orescent protein (RFP), are unique, because they 
naturally fluoresce without the addition of sub-
strates or enzymes, allowing genetic expression to 
be observed in living cells. Reporter systems based 
on the expression of fluorescence proteins are 
widely used in molecular biology and cell biology, 
and are becoming more widely applied in small 
animal imaging.24 Fluorescent proteins are partic-
ularly useful because of their stability and the fact 
that their chromophores are formed by autocata-
lytic cyclization, which does not require a cofactor. 
GFP was the first discovered fluorescent protein 
isolated from the jellyfish Aequorea victoria.25 The 
emission peak of GFP is at 509 nm, which is in the 
lower green portion of the visible spectrum. Thus, 
a newly discovered RFP that shares many proper-
ties with GFP and can be applied in a similar manner 
was developed with a longer wavelength. One form 
of RFP (DsRed) isolated from Discosoma striata has 
an optimal absorption at 558 nm and emits light at 
583 nm,26 allowing it to produce less background 
interference than GFP. The greatest advantage of 
fluorescent proteins with emission spectra peaks 
in the 450−650 nm region is that their unique emis-
sion wavelengths make it possible to simultaneously 
image multiple targets of interest in cells and tis-
sues27 (Figure 3). However, animal fluorescence imag-
ing is hampered by low signal-to-background ratios 
and autofluorescence that limits the sensitivity and 
Figure 2 Micro-positron emission tomography imaging 
of herpes simplex virus type 1 thymidine kinase activity. 
Baby hamster kidney cells were subcutaneously injected 
on the right shoulders of severe combined immunodeficient 
mice as indicated by yellow arrows. Tumor-bearing mice 
either received no vector treatment (Tumor + , Sindbis/
tk−) or received three treatments of Sindbis/tk via intra-
peritoneal injection at a distant location from the tumor 
sites (Tumor + , Sindbis/tk +). Tumor-free control mice 
(Tumor−, Sindbis/tk−) were also included to determine 
background signals. Herpes simplex virus type 1 thymidine 
kinase activity was determined after intravenous admin-
istration of 18F-FEAU as tracer. Positron emission tomog-
raphy images were acquired in axial, coronal and sagittal 
views. Coronal and sagittal images are shown with the 
animal’s head at the bottom of the image and white 
arrows indicate activity in the urinary bladder. Signal 
intensity is presented as percent of injected dose per 
gram of tissue (%ID/g). Adapted from Tseng et al.9
Figure 3 Whole-body image of orthotopically growing 
human colon cancer cells (HCT 116)−red fluorescent pro-
tein in the green fluorescent protein nude mouse. Optical 
images were acquired by a charged-coupled device cam-
era 10 weeks after orthotopic implantation of HCT 116−red 
fluorescent protein cells. Adapted from Yang et al.27
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specificity of fluorescence imaging.28 In addition, 
the immunoge nicity of exogenous fluorescent pro-
teins also limits their application in immunocompe-
tent animals.29
Luciferase
Bioluminescence reporter genes are widely used for 
whole-body imaging of small animals. The lucifer-
ases from the firefly Photinus pyralis (Fluc) and 
Renilla reformis (Rluc) have been the most widely 
used bioluminescence reporter genes in biomedical 
research30−33 (Figure 4). In bioluminescence imaging, 
the energy is obtained from an energy-dependent 
chemical reaction catalyzed by luciferases, and part 
of the chemical energy is released as visible light 
with emission spectra that peak at wavelengths of 
490−620 nm for Fluc and 480 nm for Rluc. No external 
light source is necessary. In contrast to Fluc, which 
acts on its corresponding substrate (luciferin) in the 
presence of adenosine triphosphate,34 Rluc does 
not require adenosine triphosphate to metabolize 
its substrate (coelenterazine).35 In vivo biolumi-
nescence reporter imaging currently remains more 
sensitive than in vivo fluorescence reporter imaging 
because of the absence of autobioluminescence 
and low background activity. However, the immuno-
genicity of exogenous luciferase proteins may limit 
its application in immunocompetent animals.36
Figure 4 Bioluminescent imaging of cardiac cell trans-
plantation in living animals. A rat was transplanted with 
embryonic cardiomyoblasts expressing the luciferase 
gene that emitted significant cardiac bioluminescence 
activity at days 1, 2, 4, 8, 12 and 16 (p < 0.05 vs. con-
trol). A control rat showed background signal only. 
Adapted from Wu et al.33
A
B
Figure 5 In vivo micro-positron emission tomography 
(PET) images of mice following Ad-D2R and Ad-βGal virus 
administration. Nude mice were intravenously injected 
with 9 × 109 plaque forming unit of (A) Ad-βGal virus or 
(B) Ad-D2R virus. After virus administration, both mice 
were intravenously injected with 3-(2-[18F]fluoroethyl)-
spiperone. For each mouse, a whole body coronal image 
of 18F activity distribution was acquired by PET (left 
panel). After their PET scans, the mice were killed, fro-
zen and sectioned. The next images are photographs of 
the tissue sections (0.2 mm thickness) corresponding to 
approximately the mid thickness of the micro-PET coro-
nal section (middle panel). The autoradiographs of these 
tissue sections are shown in the right panel. Signal 
intensity is presented as percent of injected dose per 
gram of tissue (%ID/g). Adapted from MacLaren et al.7
Endogenous Reporter Genes
Dopamine 2 receptor
The dopamine 2 receptor (D2R) is a cell surface recep-
tor that has been widely used as a reporter gene for 
nuclear medicine imaging by pairing with radio-
labeled probes such as [11C]raclopride and 3-(2-[18F]
fluoroethyl)-spiperone7 (Figure 5). Because D2R is an 
endogenous gene, expression of the D2R reporter in 
living animals or humans should not invoke an im-
mune response. Targeting radiolabeled 3-(2-[18F]
fluoroethyl)-spiperone to the D2R reporter for nuclear 
medicine imaging can induce the activation of a G 
protein-coupled response, resulting in decreased 
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intracellular cyclic adenosine monophosphate lev-
els. Thus, a second-generation D2R reporter gene 
(D2R80A) has been developed to prevent this intracel-
lular signal.37 The D2R is expressed primarily in the 
brain striatum and in the pituitary gland.38 The D2R 
is one of the most well-studied receptors in nuclear 
neurosciences research but may be limited in its imag-
ing specificity for monitoring the delivery and expres-
sion of genes and cells in living animals and humans.
Transferrin receptor
Transferrin receptor (TfR) is a membrane receptor 
that can shuttle targeted superparamagnetic iron 
oxide nanoparticles into cells and can be visual-
ized with MR imaging39 (Figure 6). In this imaging 
system, an engineered human TfR that lacks the iron-
regulatory region and messenger RNA destabilization 
motifs can reduce feedback downregulation of re-
ceptor expression in response to iron uptake.40 
Thus, TfR and engineered human TfR have been 
used for in vivo MR imaging of gene expression and 
cell delivery. In addition, TfR can also be overex-
pressed in different human tumors such as breast 
cancer,41,42 and may be used to enhance tumor de-
tection and imaging. However, similar to endog-
enous D2R, TfR is widely expressed in vivo,43 which 
may limit its imaging specificity. In addition, be-
cause of the low sensitivity of MR imaging, the 
local concentration of the imaging probe needs to 
be approximately 10−3−10−5 mol/L, which is con-
spicuously higher than the concentration of 10−11−
10−12 mol/L required for PET detection.
Sodium iodide symporter
Sodium iodide symporter (NIS) is an endogenous 
membrane glycoprotein (transporter) and member 
of the sodium/solute symporter family that can 
cotransport iodine and sodium across the cell mem-
brane by the sodium/potassium adenosine triphos-
phatase.44,45 In contrast to receptors that usually 
have a 1:1 binding relationship with a radiolabeled 
ligand, NIS provides signal amplification through 
transport-mediated intracellular accumulation of 
radiolabeled anions (e.g. 123I, 124I, 131I, and 99mTcO4) 
for nuclear medicine imaging46−48 or α-emitter asta-
tine 211 (211At) for targeted radiotherapy49 (Figure 7). 
Thus, the NIS transporter could an effective re-
porter. However, the NIS imaging system cannot 
metabolically trap radiolabeled iodine at the site 
of transduced cells/tissues, resulting in the lack of 
retention of radioactivity in these regions. In addi-
tion, NIS is naturally expressed in the thyroid gland 
and stomach, and to a lesser extent in salivary and 
lactating mammalian glands, placenta, kidney epi-
thelial cells and choroid plexus,50−52 which may limit 
the sensitivity and specificity of reporter assays in 
these tissues as well as adjacent tissues.
b-Glucuronidase
β-Glucuronidase (βG) has been widely used as a 
prodrug-converting enzyme for prodrug therapy.53,54 
Targeting βG, which is selectively expressed at the 
site of the tumors, could be used for the conversion 
of relatively nontoxic prodrugs to active cytotoxic 
A B C
Figure 6 In vivo magnetic resonance imaging of mice bearing transferrin receptor (TfR) + (left arrow) and TfR− (right 
arrow) tumors after injection of transferrin conjugated monocrystalline iron oxide nanoparticles (Tf-MION). (A) 
T1-weighted coronal spin echo image. TfR− and TfR + tumors have similar signal intensities. (B) T2-weighted gradient 
echo image corresponding to the image in (A), showing substantial differences between TfR− and TfR + tumors. As 
expected, TfR-mediated cellular accumulation of Tf-MION decreases signal intensity. These differences in magnetic 
resonance signal intensity were most pronounced using T2-weighted imaging pulse sequences, consistent with the 
increased transverse relaxation rate (R2) after cellular internalization. (C) Composite image of a T1-weighted spin 
echo image obtained for anatomic detail with superimposed R2 changes after Tf-MION administration. *Difference in 
R2 changes between the TfR + and TfR− tumors. Adapted from Weissleder et al.39
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agents; this could result in an improved antitumor 
effect and a reduction in systemic toxicity com-
pared with conventional chemotherapy. Several 
glucuronide prodrugs have been synthesized that 
can be activated by βG, such as doxorubicin,55,56 
etoposide,57 camptothecin analogs,58 paclitaxel,59 
ocetaxel60 and alkylating agents.61 They are rela-
tively nontoxic owing to their hydrophilic nature, 
which prevents them from entering cells and thus 
from contact with lysosomal βG. Taking advantage 
of the ability of extracellular hydrolysis of βG, Su 
et al62 and Tzou et al63 developed a membrane-
anchored βG as a reporter gene to enzymatically 
convert a hydrophilic glucuronide probe to a hy-
drophobic reporter, which is retained at the site of 
βG expression, to assess the location and expression 
of genes and cells in living animals. The βG reporter 
was constructed by fusing βG (mouse or human) 
with extracellular-transmembrane-cytosolic domains 
of B7-1 antigen (mouse or human) to anchor the 
chimeric protein on the surface of mammalian cells. 
The βG reporter can specifically hydrolyze a non-
fluorescent probe (fluorescein di-β-D-glucuronide) 
to a highly fluorescent imaging agent for optical 
imaging62 (Figure 8A), or hydrolyze isotope-labeled 
phenolphthalein glucuronide (PTH-G) to phenol-
phthalein (PTH) for PET63 (Figure 8B). Thus, the βG 
reporter is designed to retain imaging specificity 
while displaying low immunogenicity in living ani-
mals and humans.
However, there is a problem with the βG reporter 
for in vivo imaging. Glucuronide-based probes such 
as 124I-PTH-G can be transported into bile through 
multiple resistance-associated protein 2 and subse-
quently removed via the intestine,64 where intesti-
nal flora are located, which may cause 124I-PTH-G 
activation. Several methods can help overcome the 
nonspecific signal produced by bacterial βG and 
improve specific detection of the βG reporter in 
mice. First, before 124I-PTH-G injection, mice can 
be pretreated with antibiotics to clear intestinal 
microbes, although this might lead to repopulation 
of pathogenic flora. Second, PTH-G excretion may be 
shunted from the biliary to the urinary pathway. 
Repeated administration of acetaminophen can in-
crease expression of multiple resistance-associated 
protein 3 and drive the elimination of xenobiotic 
glucuronides through the urinary pathway.65 In ad-
dition, probenecid can inhibit multiple resistance-
associated protein 2 and reduce biliary excretion 
of glucuronides.66 Increased urinary elimination may 
reduce the radioactivity retained in the intestines. 
Third, since PTH-G is likely excreted through the 
biliary pathway,67 PTH can be replaced with other 
compounds that exhibit predominately urinary ex-
cretion. In this regard, the relatively hydrophobic 
chelating agent tetraazacyclododecane tetraacetic 
acid (DOTA) is efficiently removed from the blood 
via the kidneys. Gallium-68-labeled DOTA has been 
developed for cancer imaging with the use of PET,68 
which suggests that DOTA is an attractive candidate 
substitute for PTH.
Antibody reporters
Membrane-anchored antibodies are attractive for 
development of highly specific and non-immunogenic 
reporter genes.69−72 Antibody reporters can be de-
signed to exhibit low immunogenicity by employ-
ing antibodies derived from the species of interest. 
Development of humanized antibodies can mini-
mize both humoral and cellular immune responses 
to allow repeated and persistent imaging of gene 
expression or cell delivery in humans. Furthermore, 
antibody−antigen pairs possess high specificity and 
affinity without interference from cellular factors. 
5 minPost-injection:
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Figure 7 Radioiodide retention in human sodium iodide symporter (hNIS)-expressed gliomas. Rats bearing F98/hNIS 
gliomas were intravenously injected with 123I. Images were acquired at different time points by single photon emis-
sion computed tomography. The top panel shows the images acquired by a pinhole collimator in the vertex view. 
Bottom panel shows whole body images acquired simultaneously by a planar collimator in the ventral view. The pink 
arrow indicates 123I uptake in F98/hNIS gliomas and the yellow arrow indicates uptake in the thyroid. N: nasal mucosa; 
St: stomach; B: bladder. Adapted from Cho et al.47
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Northrop et al72 developed the first antibody reporter 
gene based on the expression of anti-fluorescein 
single chain antibody variable fragment on the cell 
surface to trap an imaging probe consisting of fluo-
rescein isothiocyanate coupled to the chelator di-
ethylene triamine pentaacetic acid labeled with 
isotope. However, fluorescein may be incorporated 
into the chromosome and cause cell death or 
tumorigenicity.73 Recently, a membrane-anchored 
anti-polyethylene glycol (anti-PEG) antibody was 
developed as a versatile and universal reporter gene 
that can trap a wide range of pegylated imaging 
probes. Se lective retention of pegylated probes at 
sites of anti-PEG reporter expression can facilitate 
monitoring of the delivery and expression of genes 
or cells in vivo by multiple imaging systems including 
optical imaging, MR imaging and PET13 (Figure 9). The 
anti-PEG reporter gene exhibits a high imaging spe-
cificity comparable with the gold standard reporter 
gene (HSV1-tk). In addition, the anti-PEG reporter 
does not induce a humoral immune response, which 
is in contrast to the HSV1-tk reporter that induces 
a strong antibody response in immunocompetent 
mice. Moreover, the humanized anti-PEG reporter 
was also developed to minimize human anti-mouse 
immune responses and thus allow repeated and per-
sistent imaging of the reporter in humans, increas-
ing the clinical utility of anti-PEG reporter.
The anti-PEG reporter system possesses several 
advantages including: (1) high affinity and specifi-
city of the reporter probe interaction to allow sta-
ble retention of the probes at anti-PEG-expressing 
sites; (2) the anti-PEG (or humanized anti-PEG) re-
porter can circumvent immune responses enabling 
repeated and persistent imaging of gene expression 
in mice or humans; (3) PEG is a water-soluble, non-
toxic, non-antigenic and biocompatible polymer that 
has been approved by the US Food and Drug Ad-
ministration for human use.74 Pegylation is a proven 
technology, and many pegylated probes such as 
pegylated superparamagnetic iron oxide,75 pegy-
lated fluorescent probes76 and pegylated chelating 
agents77 are in commercial or late stage clinical tri-
als. Thus, the anti-PEG reporter may be a valuable 
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Figure 8 Imaging of the β-glucuronidase (βG) reporter by multiple imaging systems. (A) In vivo optical imaging of 
mice bearing CT26 (left) and CT26/mβG-eB7 (right) tumors after intravenous injection of fluorescein di-β-D-glucuronide. 
The whole-body images were acquired at the indicated times. Micro-positron emission tomography images of βG-
expressing tumors in vivo (adapted from Su et al62). (B) In vivo micro-positron emission tomography of BALB/c mice 
bearing CT26/βG (arrows) and parental CT26 (arrowheads) tumors after intravenous injection of 124I-phenolphthalein 
glucuronide. The whole-body images were acquired in coronal planes (upper panel) and transverse planes (lower 
panel). Adapted from Tzou et al.63
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tool to image the location and delivery of gene 
therapy or cell therapy, the progression of autoim-
mune diseases, and the survival of organ transplants 
in animals and humans.
Conclusion
Reporter gene imaging techniques can be used as a 
noninvasive convenient method to evaluate gene 
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Figure 9 Imaging of the anti-polyethylene glycol (anti-PEG) reporter by multiple imaging systems. (A) In vitro optical 
imaging of human bladder cancer (EJ)/anti-PEG cells (open histogram) or control EJ/anti-DNS cells (filled histogram) 
stained with graded concentrations of the pegylated fluorescent probe (PEG-NIR797). Bars: standard error of the 
mean. (B) In vivo optical imaging of mice bearing EJ/anti-PEG tumors (right hind legs) and EJ/anti-DNS tumors (left hind 
legs) at 4, 24 and 48 hours post-injection of PEG-NIR797. (C) In vitro magnetic resonance (MR) imaging of EJ/anti-PEG 
cells (lower row) or EJ/anti-DNS cells (upper row) stained with graded concentrations of pegylated superparamagnetic 
iron oxide. (D) In vivo MR imaging of mice bearing EJ/anti-PEG tumors (solid line) and EJ/anti-DNS tumors (dashed line) 
at 1, 2 and 24 hours post-injection of PEG-superparamagnetic iron oxide. Note the darker images in the EJ/anti-PEG 
tumors. (E) In vitro binding of four-arm 124I-PEG-SHPP to EJ/anti-PEG cells (filled circles) or EJ/anti-DNS cells (open 
circles) after staining with graded concentrations of four-arm 124I-PEG-SHPP. (F) In vivo micro-positron emission tomog-
raphy of mice bearing EJ/anti-PEG tumors (right hind legs) and EJ/anti-DNS tumors (left hind legs) at 4, 24 and 48 hours 
post-injection of four-arm 124I-PEG-SHPP. Micro-positron emission tomography images were acquired at the coronal 
planes (upper panels) and transverse planes (lower panels). DNS: 5-(dimethylamino)naphthalene-1-sulfonyl; SHPP: 
3-(4-hydroxyphenyl) propionic acid N-hydroxysuccinimide ester; αDNS: anti-DNS; αPEG: anti-PEG.
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expression and cell delivery in experimental studies 
and clinical trials, as well as in the studies of trans-
genic animals. An ideal reporter should be specific 
and non-immunogenic to achieve selective localiza-
tion of imaging probes and to minimize tissue dam-
age to allow repeated and persistent imaging of gene 
expression or cell delivery in vivo. In addition, a ver-
satile reporter that can be monitored by multiple 
imaging systems will broaden its utility in biomedi-
cal research. Approaches using GFP and luciferase as 
reporter genes in humans, however, are limited by 
the immunogenicity of the reporter gene products 
as well as by the poor spatial resolution of the de-
tection system. HSV1-tk allows selective retention 
of radiolabeled substrates that can be detected by 
PET and single photon emission computed tomog-
raphy. Unfortunately, the exogenous HSV1-tk gene 
product can induce immune responses, which could 
result in tissue damage. Using endogenous report-
ers (e.g. D2R, TfR and NIS) for selective uptake of 
their radiolabeled ligands has been demonstrated 
to prevent immune responses against reporters, 
but these endogenous reporters are also widely ex-
pressed in vivo, limiting their imaging specificity. 
In addition, these natural reporters (receptor or 
transporter) can lead to initiation of intracellular sig-
naling through ligand binding. In contrast, membrane-
anchored antibody reporters, especially anti-PEG 
reporter, possess a high imaging specificity and non-
immunogenecity (from the species of interest) to 
monitor the expression and delivery of genes and 
cells in vivo by multiple imaging systems (e.g. op-
tical imaging, MR imaging and PET). Thus, the anti-
PEG reporter paired with pegylated probes may have 
great clinical potential to optimize gene therapy 
or cell therapy protocols in the clinic.
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